Entasis Therapeutics Holdings Inc. (ETTX)
3.1000 0.00 (0.00%)
After hours: 5:27PM EST
Chart Events
Performance Outlook
| Previous Close | 3.0100 |
| Open | 3.0200 |
| Bid | 2.9000 x 1000 |
| Ask | 3.1000 x 2200 |
| Day's Range | 2.9001 - 3.1000 |
| 52 Week Range | 1.5800 - 5.6400 |
| Volume | 615,246 |
| Avg. Volume | 754,464 |
| Market Cap | 109.974M |
| Beta (5Y Monthly) | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9220 |
| Earnings Date | Mar 09, 2021 - Mar 15, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.50 |
Fair Value
Related Research
- GlobeNewswire
Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference
WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. The Company’s presentation will be available on demand starting Monday, January 11th, 2021 at 6:00 AM ET, to those attending the conference virtually.About Entasis Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.Entasis Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.comInvestor Relations Contact James Salierno The Ruth Group (646) 536-7028 jsalierno@theruthgroup.comMedia Contact Annika Parrish The Ruth Group (720) 412-9042 aparrish@theruthgroup.com
- Simply Wall St.
We Think Entasis Therapeutics Holdings (NASDAQ:ETTX) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- GlobeNewswire
Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium
WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19th, 2020. The event will consist of 1-on-1 virtual investor meetings. Investors attending the conference virtually who are interested in meeting with Company management should contact their A.G.P. representative.About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.Entasis Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.comInvestor Relations Contact James Salierno The Ruth Group (646) 536-7028 jsalierno@theruthgroup.comMedia Contact Annika Parrish The Ruth Group (720) 412-9042 aparrish@theruthgroup.com
